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Background: Therapeutic decisions in cancer are generally guided by molecular biomarkers or, for some newer
therapeutics, primary tumor genotype. However, because biomarkers or genotypes may change as new metastases
emerge, circulating tumor cells (CTCs) from blood are being investigated for a role in guiding real-time drug selection
during disease progression, expecting that CTCs will comprehensively represent the full spectrum of genomic changes
in metastases. However, information is limited regarding mutational heterogeneity among CTCs and metastases in
breast cancer as discerned by single cell analysis. The presence of disseminated tumor cells (DTCs) in bone marrow also
carry prognostic significance in breast cancer, but with variability between CTC and DTC detection. Here we analyze a
series of single tumor cells, CTCs, and DTCs for PIK3CA mutations and report CTC and corresponding metastatic
genotypes.
Methods: We used the MagSweeper, an immunomagnetic separation device, to capture live single tumor cells from
breast cancer patients’ primary and metastatic tissues, blood, and bone marrow. Single cells were screened for
mutations in exons 9 and 20 of the PIK3CA gene. Captured DTCs grown in cell culture were also sequenced for PIK3CA
mutations.
Results: Among 242 individual tumor cells isolated from 17 patients and tested for mutations, 48 mutated tumor cells
were identified in three patients. Single cell analyses revealed mutational heterogeneity among CTCs and tumor cells
in tissues. In a patient followed serially, there was mutational discordance between CTCs, DTCs, and metastases, and
among CTCs isolated at different time points. DTCs from this patient propagated in vitro contained a PIK3CA mutation,
which was maintained despite morphological changes during 21 days of cell culture.
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Conclusions: Single cell analysis of CTCs can demonstrate genotypic heterogeneity, changes over time, and
discordance from DTCs and distant metastases. We present a cautionary case showing that CTCs from any single blood
draw do not always reflect metastatic genotype, and that CTC and DTC analyses may provide independent clinical
information. Isolated DTCs remain viable and can be propagated in culture while maintaining their original mutational
status, potentially serving as a future resource for investigating new drug therapies.
Keywords: Cancer cell culture, Circulating tumor cells (CTCs), Disseminated tumor cells (DTCs), Heterogeneity, Mutation
analysis, PIK3CA, Single cell analysisBackground
Clinical use of some newer or investigational drug ther-
apies in cancer requires that primary tumors be assayed
for specific mutations associated with response or lack
of response [1-5]. However, not only are primary tumors
known to be mutationally heterogeneous [6-8], new
mutations may become apparent in recurrent tumors,
emerging during disease progression [9-11]. Yet sequen-
tial biopsy and evaluation of molecular biomarkers and
mutations in metastases is not routinely done, even dur-
ing clinical trials [11], largely due to the multiplicity and
internal location of many metastases (such as liver, lung,
and/or brain metastases in breast cancer), and potential
morbidity associated with sequential biopsy. An appea-
ling alternative is a “liquid biopsy” with CTC capture
and characterization [12,13]. As they are easily accessible
by simple blood draw, CTCs can be sequentially sampled
at multiple time points during the course of disease for
biomarker or genotype determination. Moreover, it is
hoped, but not ascertained, that CTCs represent mix-
tures of tumor cells that reflect the full spectrum of mo-
lecular phenotypes and genotypes present in multiple
metastases.
Following a slightly different tack, some groups are
also investigating biomarker and genetic characteristics
of DTCs from bone marrow [14-16], which are postu-
lated to serve as a reservoir for active and dormant
tumor cells [12,17]. However, genetic analyses of muta-
tions in CTCs and DTCs are still in an early discovery
stage, having been done on few patients, so clinical sig-
nificance and utility is postulated but remains unproven.
Moreover, it is not known whether CTC analysis can re-
place DTC analysis for there is, as yet, incomplete un-
derstanding of the relationship between these two
populations [18].
In the present study, we used a previously described
magnetic separation technology that isolates live single
cells [19-21] for mutation analysis of single cells from dif-
ferent compartments in metastatic breast cancer patients
and also demonstrate growth in culture of patient DTCs
from bone marrow. For single CTC/DTC/tumor mutation
analysis, we have chosen to interrogate exons 9 and 20 of
the PIK3CA gene, one of the most frequently mutatedgenes in breast cancer [22-25]. We demonstrate that this
mutation can be detected in single tumor cells isolated
from breast cancer patient primary tumor, blood, bone
marrow, and metastases, and track mutational status
of CTCs over time in a metastatic breast cancer case
example and in cultured DTCs from this patient. While
we have previously shown that individual CTCs in breast
cancer, even from the same blood draw, are transcriptio-
nally heterogeneous [21], here we investigate mutational
heterogeneity and concordance among CTCs, DTCs, and
single tumor cells from primary tumors and metastases.
In particular, for CTCs to be ultimately used to guide drug
selection, we hypothesized that CTCs should indeed con-
tain the mutational changes found in metastases. How-
ever, our results were surprising and we present here a
case that provides a cautionary note that CTCs from any
one blood draw alone may not always represent the muta-




This study protocol was approved by Stanford’s Human
Subjects Research and Institutional Review Board (Protocol
5630). Written informed consent was explained and signed
by all participating patients prior to sample collection.
Tumor cell isolation, staining, and culture
Single cell suspensions used for MagSweeper tumor cell
isolation were prepared from primary and metastatic
tissue from breast cancer patients. Tumor chunks were
finely minced, gently pulled to release single cells or small
cell clusters, filtered through a 70 micron mesh followed
by centrifugation of the filtrate at 1900 g. The supernatant
was discarded and the pellet was resuspended in 1x tryp-
sin (Invitrogen/Life Technologies, Carlsbad, CA, USA) for
5–10 minutes. DMEM culture media with 10% FBS
(Gibco/Life Technologies, Carlsbad, CA, USA) was added
to stop the trypsin reaction. The target single tumor
cells were labeled with EpCAM-conjugated microbeads
and isolated by the MagSweeper as previously described
[19,21]. Individual tumor cells were aspirated under di-
rect microscopic visualization (Axio Observer A1, Zeiss,
Deng et al. BMC Cancer 2014, 14:456 Page 3 of 12
http://www.biomedcentral.com/1471-2407/14/456Thornwood, NY, USA). Authenticated MCF7 and BT474
human breast cancer cell lines (ATCC, Manassas, VA,
USA) were grown in DMEM and trypsinized to release
single cells, which were then isolated by the MagSweeper
and manually aspirated as single cells.
For immunostaining assays, EpCAM-captured cells were
treated with DNase I Solution (StemCell Technologies,
Vancouver, BC, Canada) to remove the DNA-linker on the
magnetic microbeads, and placed on slides. Tumor cells
were defined by immunostain assay [26-28] as cells that
stained positive for purified anti-cytokeratin (CK+) CAM
5.2 (BD Biosciences, San Jose, CA, USA) and DAPI nuclear
stain (DAPI+) (VECTASHIELD Mounting Medium with
DAPI, Vector Laboratories, Burlingame, CA, USA), and
negative for CD45 (CD45-) (CD45 Ab-1/Bra55, Neo-
Markers Lab Vision, Thermo Fisher Scientific, Kalamazoo,
MI, USA). White blood cells (WBCs) from patients
were collected using the MagSweeper and CD45 Dyna-
beads (Invitrogen, Carlsbad, CA, USA) and similarly
immunostained.
Bone marrow aspirates obtained from the clinic were
filtered through a 70 micron mesh to eliminate debris;
the passed through solution was adjusted to 10 ml by
adding DMEM. DTCs from the prepared bone marrow
sample solution were isolated by the MagSweeper and
hundreds of DTCs were directly cultured in DMEM
with 10% FBS and 50 μg/ml of penicillin-streptomycin
(Gibco/Life Technologies, Carlsbad, CA, USA). The cells
were then identified by immunostaining assays. The
DTCs were cultured for 21 days and single cells were
assayed for mutation detection.
Blood sample collection and MagSweeper isolation of
CTCs were isolated as previously described [19,21].
White blood cells (n = 15, from the blood of Patient 12)
were collected using anti-CD45 microbeads.
Mutation analysis
Single tumor cells from 17 breast cancer patients were
lysed by incubation with a 1:10 dilution of proteinase K
(Qiagen, Valencia, CA, USA) in individual PCR tubes for
20 min at 65°C in 10 μl of 1x GeneAmpPCR buffer II
(Applied Biosystems/Life Technologies, Carlsbad, CA,
USA). In one of the 17 patients, additional tumor cell
clusters were tested from slides sectioned from formalin-
fixed paraffin-embedded (FFPE) blocks of primary tumor
and a lung metastasis with location confirmed by he-
matoxylin and eosin (H&E) stain. For tumor tissue fixed
on slides, diluted proteinase K was placed on the tar-
geted tissue section area of the slide. The solution was
heated at 65°C for 20 min and collected for DNA muta-
tion analysis. The DNA from single CTC, DTC, or
tumor tissue cells was then pre-amplified for exons 9
and 20 of the PIK3CA gene, using Pfu Ultra DNA poly-
merase (Agilent Technologies, Santa Clara, CA, USA)with one set of primers for each exon (exon 9 forward pri-
mer: CTGTGAATCCAGAGGGGA, reverse primer: CAG
AGAATCTCCATTTTAGCAC; exon 20 forward primer:
GGAATGCCAGAACTACAATCTTTTG, reverse primer:
CCTATGCAATCGGTCTTTGC). The reaction was amp-
lified for 30 cycles at 94°C, 55°C, and 72°C for 30 sec per
cycle for each temperature. The pre-amplified products
were then diluted 1:10 in distilled water (DW) and 5 μl of
the diluted products were used for a single 50 μl PCR
using the same primers as above for exon 9, and an in-
ternal primer pair for exon 20 that decreased non-specific
background amplification (forward primer: GTGGAAT
CCAGAGTGAGC, reverse primer: TTGCATACATTC
GAAAGACC) [25]. PCR products were checked by 2%
agarose gel against a GeneRuler 50 bp DNA Ladder
(Frementas, Glen Burnie, MD, USA) and sequenced by
BigDye Terminator v3.1 Cycle Sequencing Kits according
to the manufacturer’s recommended protocol (Applied
Biosystems/Life Technologies, Carlsbad, CA, USA). The
sequenced results were analyzed with Sequencher 4.8 soft-
ware (Gene Codes Corporation, Ann Arbor, MI, USA).
DW was used as a negative template control. Single au-
thenticated MCF7 and BT474 cells were used as amplifi-
cation and sequencing controls: MCF7 cells contain a
G1633A mutation in exon 9 and are wild type in exon 20;
BT474 cells contain an exon 1 mutation but are wild type
in exons 9 and 20. BT20 cells, which contain the A3140G
mutation in exon 20, served as a positive control for se-
quencing of exon 20 [29]. Fifteen single WBCs isolated
from blood samples also served as wild type control for
sequencing.
Results
Patient samples and tumor cell identification
From a group of 17 breast cancer patients, single tumor
cells were collected using anti-EpCAM microbeads and
the MagSweeper from 30 blood samples, a bone marrow
biopsy, and six fresh tumor tissues (Table 1, and Table 2).
CTCs from blood, DTCs from bone marrow, and tumor
cells from fresh primary and metastatic tumors were de-
fined by immunostain assay as cells that were CK+,
CD45-, DAPI+. WBCs collected from the blood of one
patient (Patient 12) using anti-CD45 microbeads for use
as an additional wild type control for sequencing were
confirmed by immunostaining to be CK negative/very
weak, CD45 positive, and DAPI positive (Figure 1).
Overall, 769 individual CTCs from blood, 75 DTCs from
bone marrow, and 60 single TCs from fresh primary
tumor tissue (chunk and core needle biopsy), lymph
node metastasis, and a bone metastasis to the spine were
collected. Of these, 185 CTCs, 24 DTCs, 33 single TCs
from fresh primary and metastatic tissues (total 242
single cells) were collected for mutational analysis. Ad-
ditional tumor cell clusters from two FFPE samples of
Table 1 Single cell mutation analysis of CTCs
Patient ID Sample ID Sample type Number CTCs analyzed/
total CTCs collected*
Number CTCs with
PIK3CA exon 9 mutation
Number CTCs with
PIK3CA exon 20 mutation
1 1-1 Blood 3/13 0 0
1 1-2 Blood 3/9 0 0
1 1-3 Blood 4/9 0 0
2 2-1 Blood 3/20 0 0
2 2-2 Blood 2/6 0 0
2 2-3 Blood 5/50 0 0
3 3-1 Blood 3/14 0 0
4 4-1 Blood 2/8 0 0
5 5-1 Blood 2/3 0 0
6 6-1 Blood 8/75 0 0
7 7-1 Blood 5/100 0 0
8 8-1 Blood 5/60 0 0
9 9-1 Blood 2/7 0 0
10 10-1 Blood 5/200 0 0
11 11-1 Blood 5/50 0 0
12 12-1 Blood 3/6 0 0
12 12-2 Blood 2/2 0 0
12 12-3 Blood 4/4 0 0
12 12-4 Blood 13/13 0 0
12 12-5 Blood 20/20 10 0
12 12-6 Blood 7/9 2 0
12 12-7 Blood 27/27 0 ND
12 12-8 Blood 50/50 0 ND
12 12-9 Blood 0/0 - -
12 12-10 Blood 2/2 0 0
13 13-1 (BL) Blood 0/0 - -
14 14-1 (BL) Blood 0/6 - -
15 15-1 (BL) Blood 0/6 - -
16 16-1 (BL) Blood 0/0 - -
17 17-1 (BL) Blood 0/0 - -
TOTALS
17 patients 30 samples - 185/769 12 0
CTCs circulating tumor cells, ND not determined.
*CTCs not analyzed for mutations were used for transcriptional analysis [21], immunostaining, or other molecular assays.
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for PIK3CA mutations (Table 3).
DTC culture
The MagSweeper facilitates the isolation of viable target
cells that can be grown in culture. Pooled bead-captured
DTCs (Figure 2A) showed distinct morphological
changes when grown over a 21-day cell culture period
(Figure 2B and C). At the time of bone marrow biopsy,
DTCs had round shapes when examined fresh and after
capture by the MagSweeper (Figure 2A). However, on-
ward from day 5, cell shapes started varying, with somechanging to elongated or irregular shapes, although im-
munostaining assays at different stages demonstrated
that all cultured cells remained CK+, CD45- and DAPI+,
as expected of tumor cells (Figure 2B and C).
PIK3CA gene mutations
To first assess our mutation detection method, targeted
DNA from single tumor cells or cells from cell lines was
successfully pre-amplified by PCR and the expected
bands were confirmed for PIK3CA exons 9 (216 bp) and
20 (269 bp) (Figure 3A). Using the pre-amplified PCR
products as new DNA templates, exons 9 and 20 were









Number DTCs or TCs with
PIK3CA exon 9 mutation
Number DTCs or TCs with
PIK3CA exon 20 mutation
12 12-11 (T) L2 bone
metastasis
(spine)
- 8/10 8 0
12 12-12 (T) Bone marrow 24/75 - 24 0
13 13-1 (T) Primary tumor - 5/10 0 0
14 14-1 (T) Primary tumor
(core bx)
- 5/10 1 0
15 15-1 (T) LN metastasis - 5/10 3 0
16 16-1 (T) Primary tumor - 5/10 0 0






- 24/75 33/60 36 0
DTCs disseminated tumor cells from bone marrow, TCs tumor cells from primary or metastatic tumors;
LN lymph node, L2 second lumbar vertebra, Bx biopsy, ND not determined.
*DTCs or TCs not analyzed for mutations were used for immunostaining or other molecular assays.
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using the original primers and exon 20 with internal
primers. Single PCR bands for each exon verified the spe-
cificity of the amplification prior to sequencing (Figure 3B).
A known heterozygous PIK3CA exon 9 mutation, G1633A
(E545K), was identified in replicate samples of single
MCF7 cells (positive control), single DTCs, and single
CTCs, but was not detected in single WBCs (wild type/
negative control) or single BT474 cells (which carry a
PIK3CA mutation in exon 1, but no mutations in exons 9
or 20, another negative control) [30-33] (Figure 3C). Note
that A1634C (E545A) in the chromatogram in Figure 3B
sometimes showed a pseudogene that may be co-amplified
with these primers [34]. No exon 20 mutation was identi-
fied in negative control MCF7 and BT474 cells, any patient
tumor cells, or captured WBCs among our samples,
although sequencing of BT20 cells (positive control)
detected the expected exon 20 mutation at A3140GA B C
Figure 1 Single cell isolation and identification. Individual tumor
cells (TCs) from primary or metastatic tissue, blood, or bone marrow
were isolated by the MagSweeper and immunostained (200×). Panel
(A) shows examples of CTCs and DTCs (CK+, CD45-, DAPI+); small
round circles in two frames of (A) are autofluorescing residual magnetic
microbeads; Panel (B) shows an example of TCs from tumor tissue
(CK+, CD45-, DAPI+); Panel (C) shows examples of WBCs (CK-/very
weak, CD45+, DAPI+). Green = cytokeratin; red = CD45; blue = DAPI
nuclear stain.(H1047R), confirming the accuracy of our sequencing
method (Figure 3D).
PIK3CA mutation analysis was then performed on the
242 EpCAM-captured single tumor cells (185 CTCs, 24
DTCs, and 33 tumor cells). Three out of 17 (18%) patients
showed the PIK3CA exon 9 G1633A mutation in tissue;
no exon 20 mutations were detected (Table 1, Table 2 and
Table 3). Of these three patients (Patient 12, Patient 14,
and Patient 15), 33 individual tumor cells obtained from
six fresh clinical samples were sequenced and three
showed the exon 9 mutation: 8/8 (100%) single tumor
cells from a spinal bone metastasis (Patient 12); 1/5 (20%)
single tumor cells from a primary tumor core biopsy
(Patient 14); and 3/5 (60%) single tumor cells from a
metastatic lymph node (Patient 15). Not unexpectedly,
and similar to this patient’s bone metastasis, all 24 (100%)
sequenced single DTCs collected from a 3 ml aspirate of
Patient 12’s tumor-replaced bone marrow contained the
exon 9 mutation (the bone marrow aspirate had been
done to determine if tumor overgrowth was causing her
pancytopenia, and the DTCs detected were too numerous
to count). Interestingly, the FFPE sample of Patient 12’s
primary tumor was wild type, but a tissue section of
her lung metastasis also showed the PIK3CA exon 9




Sample type PIK3CA PIK3CA
Exon 9 Exon 20
12 Primary tumor Wild type Wild type
12 Lung metastasis Mutation present Wild type
Direct smear 








1b 1c 1d 1e 1f
2b 2c 2d 2e 2f




Figure 2 Live DTCs captured by the MagSweeper and propagated in vitro. (A) DTCs detected in fresh smear of bone marrow aspirate among
a background of red blood cells (RBCs) and white blood cells (WBCs) (left panel); unstained EpCAM-captured DTCs from bone marrow aspirate (right
panel); small black circles are EpCAM-conjugated microbeads. (B) EpCAM-captured tumor cells (200×) grown in culture for three weeks: tumor cells
proliferated days 1–4, but began changing shape on day 5. (C) Tumor cells identified by immunostaining at different timepoints during cell culture
period (a = day 1; b-f = day 21 at 200×); upper panel 1 shows cell morphology by brightfield; middle panel 2 shows immunostain images (all cells were
CK+, CD45- and DAPI+); lower panel 3 shows varying nuclear morphology of cells between day 1 day 21. Green = cytokeratin, red = CD45, blue = DAPI
nuclear stain.
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14 months, during changing treatment of her metastatic
breast cancer (Table 1, Table 2, Table 3 and Table 4,
Figure 4). Remarkably, in this patient with mutant DTCs
in her bone marrow and mutant tumor cells in her spinal
bone metastasis and lung metastasis, CTCs in some blood
draw samples were discordant and did not show the ex-
pected mutation. Notably, of ten blood samples collected
from this patient over time, only nine blood samples con-
tained capturable CTCs; of the 128 CTCs sequenced from
these nine samples, mutant CTCs were detected in only
two blood draws: at one and six weeks after bone marrow
biopsy, with mutant cells comprising 50% (10/20) and
29% (2/7) of EpCAM-captured cells, respectively (Table 1,
Table 2, Table 3 and Table 4, Figure 4). As expected, all 15
WBCs analyzed from this patient were wild type. Our
single cell data thus indicate that not only may there bemutational heterogeneity within a sample, there may be
genotypic discordance between CTCs, DTCs and metasta-
ses, or between CTC samples isolated at different time
points.
In addition to mutational heterogeneity and discord-
ance, this patient’s clinical pathology showed discordance
between different sites when tested for the standard breast
cancer biomarkers estrogen receptor (ER), progesterone
receptor (PR), and HER2 growth factor receptor: primary
tumor and lung were hormone receptor (ER and/or PR)
positive, whereas bone marrow and bone were hormone
receptor negative (Table 4). No tissue sample was HER2
positive.
Finally, when Patient 12’s DTCs were propagated
in vitro, all cultured cells maintained the original PIK3CA
exon 9 mutation when again tested on day 21, despite the
observed morphological changes described above.
CA
269 bp (exon 20.P1)
216 bp (exon 9)
B
192 bp (exon 20.P2)
216 bp (exon 9)

























Figure 3 Single cell PIK3CA mutation detection. (A) Target DNA from two single tumor cells (SC1, SC2) successfully pre-amplified by PCR with the
expected bands for PIK3CA exon 9 (216 bp) and exon 20 (269 bp). (B) Second round of amplification using the pre-amplified PCR products from (A) as
new DNA templates to separately amplify exon 9 (using original primers, 216 bp) and exon 20 (using internal primers, 192 bp). P1 = PCR product from
first round of amplification; P2 = PCR product from second round of amplification. (C) Sanger sequencing results for PIK3CA mutation G1633A on exon
9: two MCF7 single cells shown here carry the G1633A heterozygous mutation; Normal DNA, BT474 single cells, and single WBCs are wild type
(G/G); PIK3CA G1633A mutations were detected in single DTCs and CTCs from breast cancer patient 12. The G1633A mutation was distinguishable in
the chromatogram from the adjacent A1634C peak from a known pseudogene on chromosome 22 that may be co-amplified with these primers [34],
as in sample MCF7.2. (D) Sanger sequencing results for PIK3CA mutation A3140G on exon 20: BT20 cells show the mutation but MCF7 cells, BT474 cells,
and CTCs are wildtype for this mutation hotspot.
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Investigations are underway exploring the clinical utility
of CTCs and DTCs in monitoring cancer patients under-
going systemic drug therapy [35]. However, a recent pro-
spective randomized phase III clinical trial of patients
with metastatic breast cancer (SWOG S0500) showed
that early change in therapy based on persistently ele-
vated CTC counts three weeks after starting a drug did
not change patient outcome - likely due to poor efficacy
of the drugs these metastatic patients received after
switching therapy [36]. One upshot of this study is theexpectation that, in the future, the measurement of CTC
biomarkers or genotype, rather than only CTC enume-
ration, should offer better prediction of which drugs will
be efficacious.
However, as demonstrated here, primary tumors and
metastases can be heterogeneous, and different metasta-
ses do not always display the same biological markers. It
is not clinically feasible to biopsy all metastases in a
given patient at any one time point, and certainly not for
serial sampling over the course of disease, so it is hoped
that sampling CTCs will reflect the spectrum of tumor
Table 4 Treatments, sampling times, and biomarkers of tumor cells in different tissue compartments from patient 12
during disease progression
Date
sampled Treatment Tissue compartment ER PR HER2
PIK3CA mutation in CTCs
or DTCs or TCs (primary tumor
or distant metastasis)
09/2002 N/A Primary Tumor 1+ rare 2+, 10% Neg (IHC 0) Wild type#







9/23/2009 Exemestane Lung metastasis 3+, 95% Negative Neg
(FISH ratio 0.56)
Mutation present†
9/30/2009 Tamoxifen started Blood - - - 0/3
10/8/2009 Tamoxifen Blood - - - 0/2
1/21/2010 Fulvestrant Blood - - - 0/4
2/4/2010 Fulvestrant Blood - - - 0/13
3/4/2010 Fulvestrant Bone marrow biopsy Negative Negative Negative 24/24
3/11/2010 Cyclophos-phamide started Blood - - - 10/20
4/15/2010 Cyclophos-phamide Blood - - - 2/7
7/1/2010 Cyclophos-phamide Blood - - - 0/27
8/5/2010 Capecitabine + RAD001 (everolimus) Blood - - - 0/50
10/20/2010 Capecitabine + RAD001 (everolimus) Blood - - - 0/0
11/11/2010 Capecitabine + RAD001
(everolimus)
Blood - - - 0/2
CTCs circulating tumor cells (from blood), DTCs disseminated tumor cells (from bone marrow), TCs tumor cells from primary tumor or metastatic site.
All detected PIK3CA mutations were heterozygous on exon 9 G1633A (E545K).
#Tumor cells obtained and tested from both H&E slide and formalin fixed paraffin-embedded primary tumor tissue.
†Tumor cells obtained and tested from H&E slide.
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patient with progressive metastatic breast cancer, we com-
pared the PIK3CA mutation status of sequentially sampled
CTCs to that of tumor cells from two biopsied metastases
and DTCs from bone marrow. Unfortunately, and surpris-
ingly, our data did not support the premise that CTCs in
most blood draws were reflective of metastatic genotype.
While we did show that different metastases contained
discordant biomarkers (Table 4), PIK3CA mutations in
CTCs were heterogeneously present in only 2/9 serial
blood draws in this patient with multiple distant metasta-
ses, two of which (lung and spine) contained tumor cells
carrying mutations and whose bone marrow was full of
mutant DTCs.
This finding causes pause and suggests that different
factors may be at work. One may be that the CTCs ana-
lyzed here were captured using the EpCAM cell surface
marker. It is postulated that among tumor cells shed from
a tissue, many undergo epithelial-mesenchymal transition
(EMT), with expression of EMT-associated genes and pro-
teins, and we and others have demonstrated EMT gene
and protein expression in CTCs [21,37-39]. Although
CTCs in most EMT studies have been captured with
EpCAM antibodies, as EMT progresses, EpCAM expres-
sion likely diminishes. Thus, CTCs may consist of popula-
tions of EpCAM-expressing and non-EpCAM expressing
CTCs. One of the limitations of this study is that becauseof the technology applied, we studied only EpCAM-
expressing CTCs. There may be other non-EpCAM-
expressing CTCs present in the blood samples that may
have shown a mutant genotype not identified in some of
the EpCAM-expressing CTCs. While the mutant tumor
cells from metastases in our study were also captured
using anti-EpCAM magnetic beads, these cells may poten-
tially have been seeded from EpCAM-negative CTCs that
had undergone mesenchymal-epithelial-transition after
lodging and growing in the metastatic site, with re-
expression of EpCAM on their cell surface. We are now
testing different cell surface markers and label-free cap-
ture technologies to address this issue, which is parti-
cularly important because of recent data suggesting an
association between EpCAM-negative CTCs and brain
metastases [40].
A second limitation or explanation of our findings is
that we do not know the role of drug treatment in sup-
pressing the appearance of mutant tumor cells in the cir-
culation. For example, at the time that 50 of Patient 12’s
CTCs showed no mutation, the patient was receiving
RAD001 (everolimus), an mTOR inhibitor that may be
more active against cells carrying PIK3CA mutations
[41]; her CTC count subsequently dropped to zero, per-
haps showing response to therapy over time.
A third limitation may be that sequencing only two
common hotspots on the PIK3CA gene may miss other
Figure 4 PIK3CA G1633A mutation detection in CTCs and tissues over time. One patient, Patient 12, with progressive metastatic breast cancer
underwent tissue evaluation and PIK3CA sequencing of a bone (spine) metastasis, lung metastasis, bone marrow biopsy and aspirate (DTCs), and
sequential blood draws for one and a half years. Eight out of 10 EpCAM-captured single cells (two cells did not get PCR products for sequencing) in
the core needle biopsy of a bone metastases (Bone Bx) from the lumbar spine carried the PIK3CA exon 9 heterozygous mutation G1633A; a lung
biopsy (Lung Bx) also showed this mutation; 24 out of 24 EpCAM-captured single cells analyzed from the bone marrow biopsy (BM Bx) carried the
heterozygous mutation (EpCAM-captured DTCs retrieved from the bone marrow aspirate). The G1633A mutation was detected only twice in CTCs
captured from nine blood samples: one week after bone marrow biopsy, with 10/20 EpCAM-captured cells having the mutation, and six weeks after
bone marrow biopsy, with 2/7 EpCAM captured cells having the mutation. Drug treatments are noted (RAD001 = everolimus, an mTOR inhibitor).
Note that increasing CTC counts dramatically decreased after treatment with capecitabine and everolimus.
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progressive metastatic disease, and which may have been
shared by the CTCs and metastases. Very recent and ex-
citing work is underway to develop rigorous methods for
investigating single cell whole-exome sequencing of CTCs
(also captured using MagSweeper technology) [42].
However, given current technology development, our
study is important in that it adds a note of caution to
using CTCs from only a single blood draw to depict the
mutational status in any given patient with metastatic
disease for treatment purposes. Treatment decisions
based on CTC mutational status should only be done
under the auspices of a clinical trial.
While CellSearch™ is the only FDA-approved test for
enumeration of CTCs, other CTC capture and charac-
terization technologies, including single cell analysis, are
rapidly advancing [43-46]. As sequencing technologies
progress and cost decreases, it is anticipated that CTC
and DTC genotyping will become more clinically feasible.
Genotyping of CTCs or DTCs has generally been per-
formed on pooled samples [47-53]. Studying potentially
mixed subpopulations, mutant and wild type, may not be
as informative regarding which cells respond to which
drugs. However, there are reports describing single cell
copy number alterations or mutations in CTCs or DTCs
from breast [54-56] or other cancers [12,57-60] usingarray comparative genomic hybridization and/or sequen-
cing. Like ours, these studies tend to be small, describing
only a few cases with aberrant CTC or DTC DNA, but re-
sults are encouraging. Tumor cell genotyping at the single
cell level may become important clinically because dif-
ferent tumor cell genotypes may be responsive or resistant
to different treatments. Thus, capturing and analyzing
single tumor cells using deep sequencing of cancer-related
genes may lead to even better clarification for selective
drug targeting.
However, the lack of mutational discordance between
some of the CTC blood draws in Patient 12 and the
known presence of mutations in several metastases, raises
questions regarding what tumor cells from metastases are
released into the circulation, how they may be preferen-
tially impacted by systemic chemotherapy, and whether
bone marrow biopsy would be valuable to augment CTC
information prior to switching chemotherapy. In the long
run, a prospective clinical trial would be needed to deter-
mine whether CTCs alone can optimally guide drug the-
rapy and impact survival, or whether assaying both CTCs
and DTCs may be better, or whether this is moot until
drugs are developed that will ablate metastatic cancer cells.
On a more positive note, we were able to isolate live
DTCs and propagate them in culture. Although cell
morphology changed over time, mutation status did not.
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the second to report in vitro conservation of mutational
status [16]. As extent of growth of DTCs in culture has
been previously associated with poor clinical outcome
[16], this lays the groundwork for future in vitro drug
testing experiments using novel therapeutics against
DTCs isolated in treatment-refractory patients.
Conclusions
Single cell analysis of CTCs can reveal genotypic hetero-
geneity that may change over time, and can show muta-
tional discordance with DTCs and distant metastases. We
present a case suggesting that CTCs may not always reflect
the full spectrum of mutations in metastatic disease - or
that mutant cells in the circulation may have been more
susceptible to the systemic therapy being administered. We
postulate that bone marrow may be a more privileged and
perhaps chemo-refractory site than the bloodstream, so
analyzing both CTCs and DTCs may provide independent
clinical information potentially relevant to treatment deci-
sions. Isolated DTCs remain viable and can be propagated
in culture while maintaining their original mutational sta-
tus, and thus may serve as a resource for investigating new
drug therapies in the future.
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